The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin, 68, 394, 10.3322/caac.21492 Chen, 2016, Cancer statistics in China, 2015, CA Cancer J. Clin, 66, 115, 10.3322/caac.21338 Ferlay, 2020 Iyer, 2013, Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany, Lung Cancer, 81, 288, 10.1016/j.lungcan.2013.03.008 Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N. Engl. J. Med, 346, 92, 10.1056/NEJMoa011954 Socinski, 2018, Current and emergent therapy options for advanced squamous cell lung cancer, J. Thorac. Oncol, 13, 165, 10.1016/j.jtho.2017.11.111 Jotte, 2020, Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial, J. Thorac. Oncol, 15, 1351, 10.1016/j.jtho.2020.03.028 Paz-Ares, 2020, A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407, J. Thorac. Oncol, 15, 1657, 10.1016/j.jtho.2020.06.015 Paz-Ares, 2019 Zhang, 2018, The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions, Cancer Immunol. Immunother, 67, 1079, 10.1007/s00262-018-2160-x Dahan, 2015, FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis, Cancer Cell, 28, 285, 10.1016/j.ccell.2015.08.004 Desai, 2020, Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors, J. Immunother. Cancer, 8, 10.1136/jitc-2019-000453 Wang J., Lu S., Yu X., et al. Phase 3 Study of Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone As First-Line Treatment For Advanced Squamous Non-Small Cell Lung Cancer American Society of Clinical Oncology. Chicago, IL2020. Shen, 2020, Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study, J. Immunother. Cancer, 8, 10.1136/jitc-2019-000437 Wang, 2021, Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer: a phase 3 randomized clinical trial, JAMA Oncol Iyer, 2014, The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study, Support Care Cancer, 22, 181, 10.1007/s00520-013-1959-4 Dai, 2017, Changes in and determinants of quality of life in patients with advanced non-small-cell lung cancer undergoing initial chemotherapy, J. Nurs. Res, 25, 203, 10.1097/JNR.0000000000000148 Lee, 2011, Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls, Qual. Life Res, 20, 415, 10.1007/s11136-010-9761-y Garassino, 2020, Lancet Oncol, 21, 387, 10.1016/S1470-2045(19)30801-0 Reck, 2019, Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial, Eur. J. Cancer, 116, 137, 10.1016/j.ejca.2019.05.008 Brahmer, 2017, Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial, Lancet Oncol, 18, 1600, 10.1016/S1470-2045(17)30690-3 Bergman, 1994, The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC study group on quality of life, Eur. J. Cancer, 30a, 635, 10.1016/0959-8049(94)90535-5 Aaronson, 1993, The European organization for research and treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J. Natl. Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Kemmler, 1999, Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European organization for research and treatment of cancer quality of life questionnaire-C30, J. Clin. Oncol, 17, 2932, 10.1200/JCO.1999.17.9.2932 Zeger, 1986, Longitudinal data analysis for discrete and continuous outcomes, Biometrics, 42, 121, 10.2307/2531248 Dajczman, 2008, Should patient-rated performance status affect treatment decisions in advanced lung cancer?, J. Thorac. Oncol, 3, 1133, 10.1097/JTO.0b013e318186a272 Basch, 2016, Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial, Clin. Trials, 13, 331, 10.1177/1740774515615540 Koller, 2017, An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients, Ann. Oncol, 28, 2874, 10.1093/annonc/mdx453